Results 141 to 150 of about 85,599,608 (253)

DPP-4 Inhibitor Improved the Cognitive Function in Diabetic Rats. [PDF]

J Healthc Eng, 2022
Hu Y, Wang J, Wang J, Chen W, Zhang Q.
europepmc   +1 more source

Reduction of Angiotensin II Induced Hypertension and Cardiac Fibrosis with GLP-1 Receptor Agonist and DPP-4 Inhibitor via Decreasing NADPH Oxidase Expression

, 2020
This study entails focus on Ang II infused cardiac fibrosis, NADPH oxidases role in the inflammation pathway, and possible treatment options in GLP-1 agonists and DPP-4 ...
Trenton Banks
core  

The SGLT2i Treatment Gap in UK Primary Care: A Cross‐Sectional RWE Study of Prescribing in Clinical Practice

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) improve cardiovascular and renal outcomes in type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD) and chronic heart failure (CHF). Despite clinical guideline recommendations, SGLT2i uptake in UK primary care remains suboptimal and information on utilisation is limited.
Chelsea Stefanska, Ryan Chung, Salman Ramjaun, Danyao Jin, Ciara Doherty, Kieran McCafferty, Samuel Seidu   +6 more
wiley   +1 more source

RS3PE Syndrome with Subsequent PMR Caused by Long-Term DPP-4 Inhibitor Use. [PDF]

Eur J Case Rep Intern Med, 2023
Takahashi Y, Deshpande GA, Kanai Y, Seok Yan K, Naito T.   +4 more
europepmc   +1 more source

A 52‐Week Efficacy and Safety Study of Teneligliptin, as an Add‐On to Empagliflozin and Metformin in Patients With Type 2 Diabetes Mellitus: A Randomised, Double‐Blind, Placebo‐Controlled Phase 3 Trial (TERA305 Study)

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the long‐term efficacy and safety of teneligliptin add‐on in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and empagliflozin. Materials and Methods In this randomised, double‐blind, phase 3 trial, 214 patients received teneligliptin 20 mg (n = 107) or placebo (n = 107) once daily for 24 ...
Jun Sung Moon, Kyung Ah Han, Dong‐Lim Kim, Sang Yong Kim, Soo‐Kyung Kim, Bon Jeong Ku, Woo Je Lee, Tae Keun Oh, Ji A Seo, Sang‐Ah Chang, Moon‐Kyu Lee, Kyu Jeung Ahn, Chul Sik Kim, Tae Nyun Kim, Bong‐Soo Cha   +14 more
wiley   +1 more source

Comparative effects of second-line oral antidiabetic medications on atrial fibrillation risk in patients with type 2 diabetes: a nationwide retrospective cohort study

Cardiovascular Diabetology
Backgrounds Despite numerous studies investigating the effects of antidiabetic medications on cardiovascular outcomes, the optimal second-line oral antidiabetic medication for atrial fibrillation (AF) prevention remains unclear.
Ga Young Heo, Seok-Jae Heo, Byounghwi Ko, Ye Eun Ko, Hee Byung Koh, Cheol Ho Park, Jung Tak Park, Seung Hyeok Han, Tae-Hyun Yoo, Shin-Wook Kang, Minkyung Han, Hyung Woo Kim   +11 more
doaj   +1 more source

A Case of Euglycemic Diabetic Ketoacidosis (DKA), Influenza, and a Dipeptidyl Peptidase-4 (DPP-4) Inhibitor. [PDF]

Cureus, 2023
Jeong SH, Vorachitti M, Fuentes F.
europepmc   +1 more source

Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy in elderly type 2 diabetes patients in Thailand

, 2016
Unchalee Permsuwan,1 Piyameth Dilokthornsakul,2 Surasak Saokaew,2–4 Kednapa Thavorn,5–7 Nathorn Chaiyakunapruk2,4,8,9 1Faculty of Pharmacy Chiang Mai University, Chiang Mai, 2Center of Pharmaceutical Outcomes Research, Faculty of ...
Chaiyakunapruk N, Thavorn K, Dilokthornsakul P, Permsuwan U, Saokaew S   +4 more
core  

Differential Effects of PPAR-γ Activation vs. Chemical or Genetic Reduction of DPP-4 Activity on Murine Bone Quality [PDF]

, 2011
This study characterized the effects of two anti-diabetic drugs, a thiazolidinedione (TZD) and a Dipeptidyl Peptidase-4 (DPP-4) inhibitor on bone quality in a glucose intolerant mouse model.
Kyle, Kimberly Anne
core  

Real‐World Cost and Utilisation Burden of Diagnosed Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes in the United States: A Retrospective Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This study quantified the real‐world healthcare costs and utilisation associated with diagnosed metabolic dysfunction‐associated steatotic liver disease (MASLD) among adults with Type 2 diabetes (T2D). Methods We conducted a retrospective cohort study using IQVIA PharMetrics Plus Closed Health Plan data from January 2016 to June 2025 ...
Tien Hoang Tran, Hyung‐Seok Kim, Rozalina G. McCoy, Zafar Zafari   +3 more
wiley   +1 more source